Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
Related Posts
Hao Q, Henning SM, Magyar CE, Said J, Zhong J, Rettig MB, Vadgama JV, Wang P. Correction: Hao et al. Enhanced Chemoprevention of Prostate Cancer[...]
Daniels GM, Caldwell KE, Tou AM, Erickson TS, Curran M, Sullivan AJ, Phung A, Colucci L, Asaad M, Radut B. Reclaiming Values-Driven Education: An Exploration[...]
Chadha P, Kang EH, Ngo V, Jorrin R, Kochai K, Ackerman-Barger K, Ton H. Supporting Educational Excellence in Diversity (SEED): faculty development and allyship. BMC[...]